Ocular CDO sells 3,035 shares at $10.77 for taxes

OCULAR THERAPEUTIX, INC (OCUL) officer Peter Kaiser, Chief Development Officer, reported a sale of 3,035 shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share.

Rhea-AI Filing Summary

OCULAR THERAPEUTIX, INC (OCUL) officer Peter Kaiser, Chief Development Officer, reported a sale of 3,035 shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share. The transaction was executed under a pre-arranged durable automatic sale instruction to cover tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. After this sale, Kaiser directly holds 264,378 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

Insider Trade Summary 10b5-1

Net Seller: 3,035 shares

Net Sell 1 txn

Insider Kaiser Peter

Role Chief Development Officer

Sold 3,035 shs ($33K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	3,035	$10.77	$33K

Holdings After Transaction: Common Stock — 264,378 shares (Direct)

Footnotes (3)

1. F1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6429 to $10.9125, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
3. F3. Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

Key Figures

Shares sold: 3,035 shares of common stock Weighted average sale price: $10.77 per share Sale price range: $10.6429 to $10.9125 per share +2 more

5 metrics

Shares sold 3,035 shares of common stock Sale on August 24, 2026 by Chief Development Officer Peter Kaiser

Weighted average sale price $10.77 per share Weighted average for 3,035 shares sold on August 24, 2026

Sale price range $10.6429 to $10.9125 per share Price range of multiple transactions included in the reported sale

Shares owned after transaction 264,378 shares Direct holdings of Peter Kaiser following the August 24, 2026 sale

ESPP shares included in holdings 1,272 shares Shares acquired under the Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026

Key Terms

durable automatic sale instruction, sell-to-cover election, restricted stock units, weighted average price, +1 more

5 terms

durable automatic sale instruction regulatory

"shares of common stock ... sold, pursuant to a durable automatic sale instruction adopted"

sell-to-cover election financial

"effecting the sell-to-cover election of the reporting person to satisfy tax"

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Purchase Plan financial

"acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OCUL executive Peter Kaiser report?

Peter Kaiser reported selling 3,035 OCUL shares of common stock on August 24, 2026, at a weighted average price of $10.77 per share in a non-discretionary, pre-arranged sale primarily to cover tax withholding on vesting restricted stock units.

Was the OCUL insider sale by Peter Kaiser under a Rule 10b5-1-type plan?

The sale was made under a durable automatic sale instruction adopted on April 9, 2024, effecting a sell-to-cover election for tax withholding on RSUs vesting on August 22, 2026. The filing’s Rule 10b5-1 checkbox is marked as affirmed.

What price range were Peter Kaiser’s OCUL shares sold at?

The filing states a weighted average price of $10.77 per share. Individual trades occurred in multiple transactions at prices ranging from $10.6429 to $10.9125, inclusive. Full price breakdowns are available from the reporting person upon request.

How many OCUL shares does Peter Kaiser own after the reported sale?

Following the reported transaction, Peter Kaiser directly owns 264,378 shares of OCULAR THERAPEUTIX, INC common stock. This amount includes 1,272 shares acquired through the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

What is the purpose of Peter Kaiser’s OCUL share sale?

The sale of 3,035 shares was made to satisfy tax withholding obligations related to the vesting of restricted stock units on August 22, 2026. The filing specifies that these sales do not represent a discretionary trade by Peter Kaiser.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 06:00 PM EDT Accepted by SEC EDGAR 08/26/2026 - 05:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaiser Peter

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

14 CROSBY DRIVE, 3RD FLOOR

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/24/2026		S(1)		3,035(1)	D	$10.77(2)	264,378(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6429 to $10.9125, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

	/s/ Todd Anderman, Attorney-in-Fact for Peter Kaiser	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)